BioLineRx to Report First Quarter 2026 Results on May 27, 2026
Rhea-AI Summary
BioLineRx (NASDAQ: BLRX) will report unaudited Q1 2026 results on May 27, 2026, before U.S. markets open. Management will host a conference call at 8:30 a.m. EDT with CEO Philip Serlin, accessible via phone, live webcast, and replay.
Positive
- None.
Negative
- None.
News Market Reaction – BLRX
In the May 20 session, BLRX gained 4.56%, reflecting a moderate positive market reaction. Argus tracked a peak move of +4.7% during that session. Argus tracked a trough of -3.6% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 16 | Earnings date notice | Neutral | -4.1% | Set date and call details for release of 2025 annual results. |
| Nov 18 | Earnings date notice | Neutral | -5.3% | Announced timing and conference call for Q3 2025 results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings date notices for BLRX saw consistently negative next-day moves, with an average change of -4.71% across the provided events.
Over recent months, BioLineRx has combined financial reporting with steady clinical progress. The company last reported full-year 2025 results with a corporate update on March 23, 2026, while GLIX1 advanced through initiation and early execution of a Phase 1/2a GBM trial. Separate earnings date notices on November 24, 2025 and March 23, 2026 were followed by single‑day declines of -5.31% and -4.12%, suggesting that scheduling announcements have historically coincided with modest downside pressure.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management to Hold Conference Call at 8:30 a.m. EDT
The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.
To access the conference call, please dial +1-888-407-2553 from the
About BioLineRx
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial has been initiated in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.
The Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide in solid tumors, including metastatic pancreatic cancer (PDAC), and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.
Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on LinkedIn.
CONTACTS:
Chuck Padala
LifeSci Advisors, LLC
IR@biolinerx.com
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-first-quarter-2026-results-on-may-27-2026-302777565.html
SOURCE BioLineRx Ltd.